Change search
ReferencesLink to record
Permanent link

Direct link
Self-reported symptoms and motor tests via telemetry in a 36-month levodopa-carbidopa intestinal gel infusion trial
Dalarna University, School of Technology and Business Studies, Computer Engineering.ORCID iD: 0000-0002-2372-4226
Neuroscience, Neurology, Uppsala University.
Clinical Neuroscience, Karolinska Institutet.
Clinical Neuroscience, Karolinska Institutet.
Show others and affiliations
2013 (English)In: Movement Disorders :  Supplement: Abstracts of the Seventeenth International Congress of Parkinson's Disease and Movement Disorders S1, Wiley-Blackwell, 2013, S168-S168 p.Conference paper, Abstract (Refereed)
Abstract [en]


To investigate if a home environment test battery can be used to measure effects of Parkinson’s disease (PD) treatment intervention and disease progression.


Seventy-seven patients diagnosed with advanced PD were recruited in an open longitudinal 36-month study at 10 clinics in Sweden and Norway; 40 of them were treated with levodopa-carbidopa intestinal gel (LCIG) and 37 patients were candidates for switching from oral PD treatment to LCIG. They utilized a mobile device test battery, consisting of self-assessments of symptoms and objective measures of motor function through a set of fine motor tests (tapping and spiral drawings), in their homes. Both the LCIG-naïve and LCIG-non-naïve patients used the test battery four times per day during week-long test periods.



The LCIG-naïve patients used the test battery at baseline (before LCIG), month 0 (first visit; at least 3 months after intraduodenal LCIG), and thereafter quarterly for the first year and biannually for the second and third years. The LCIG-non-naïve patients used the test battery from the first visit, i.e. month 0. Out of the 77 patients, only 65 utilized the test battery; 35 were LCIG-non-naïve and 30 LCIG-naïve. In 20 of the LCIG-naïve patients, assessments with the test battery were available during oral treatment and at least one test period after having started infusion treatment. Three LCIG-naïve patients did not use the test battery at baseline but had at least one test period of assessments thereafter. Hence, n=23 in the LCIG-naïve group. In total, symptom assessments in the full sample (including both patient groups) were collected during 379 test periods and 10079 test occasions. For 369 of these test periods, clinical assessments including UPDRS and PDQ-39 were performed in afternoons at the start of the test periods. The repeated measurements of the test battery were processed and summarized into scores representing patients’ symptom severities over a test period, using statistical methods. Six conceptual dimensions were defined; four subjectively-reported: ‘walking’, ‘satisfied’, ‘dyskinesia’, and ‘off’ and two objectively-measured: ‘tapping’ and ‘spiral’. In addition, an ‘overall test score’ (OTS) was defined to represent the global health condition of the patient during a test period.

Statistical methods

Change in the test battery scores over time, that is at baseline and follow-up test periods, was assessed with linear mixed-effects models with patient ID as a random effect and test period as a fixed effect of interest. The within-patient variability of OTS was assessed using intra-class correlation coefficient (ICC), for the two patient groups. Correlations between clinical rating scores and test battery scores were assessed using Spearman’s rank correlations (rho).


In LCIG-naïve patients, mean OTS compared to baseline was significantly improved from the first test period on LCIG treatment until month 24. However, there were no significant changes in mean OTS scores of LCIG-non-naïve patients, except for worse mean OTS at month 36 (p<0.01, n=16). The mean scores of all subjectively-reported dimensions improved significantly throughout the course of the study, except ‘walking’ at month 36 (p=0.41, n=4). However, there were no significant differences in mean scores of objectively-measured dimensions between baseline and other test periods, except improved ‘tapping’ at month 6 and month 36, and ‘spiral’ at month 3 (p<0.05). The LCIG-naïve patients had a higher within-subject variability in their OTS scores (ICC=0.67) compared to LCIG-non-naïve patients (ICC=0.71). The OTS correlated adequately with total UPDRS (rho=0.59) and total PDQ-39 (rho=0.59).


In this 3-year follow-up study of advanced PD patients treated with LCIG we found that it is possible to monitor PD progression over time using a home environment test battery. The significant improvements in the mean OTS scores indicate that the test battery is able to measure functional improvement with LCIG sustained over at least 24 months.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2013. S168-S168 p.
Keyword [en]
Remote monitoring; Telemedicine; Home assessment; Parkinson's disease; Levodopa infusion
National Category
Computer Systems
Research subject
Komplexa system - mikrodataanalys, PAULINA - Uppföljning av Parkinsonsymptom från hemmet
URN: urn:nbn:se:du-12628DOI: 10.1002/mds.25605ISI: 000320940502045OAI: diva2:630753
The Movement Disorder Society's 17th International Congress of Parkinson's Disease and Movement Disorders, June 16-20 2013
Available from: 2013-06-19 Created: 2013-06-19 Last updated: 2015-06-12Bibliographically approved

Open Access in DiVA

fulltext(571 kB)130 downloads
File information
File name FULLTEXT01.pdfFile size 571 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Memedi, MevludinWestin, Jerker
By organisation
Computer Engineering
Computer Systems

Search outside of DiVA

GoogleGoogle Scholar
Total: 130 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 586 hits
ReferencesLink to record
Permanent link

Direct link